Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
3(75.0%)
Phase 2
1(25.0%)
4Total
N/A(3)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05192720Not ApplicableCompleted

Andosan in Allergic and Asthma Patients

Role: collaborator

NCT01496053Phase 2Completed

Anti-inflammatory Effect of Agaricus Blazei Murill in Inflammatory Bowel Disease (IBD)

Role: collaborator

NCT01815411Not ApplicableCompleted

Effect of Andosan in Patients With Rheumatoid Arthritis

Role: collaborator

NCT03198455Not ApplicableCompleted

Does Medicinal Mushroom Agaricus Blazei Protect Against Allergy and Asthma?

Role: collaborator

All 4 trials loaded